Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.69 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.69 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.69 |
| ▸ | APEX1 | P27695 | 2/20 | 0.56 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | KDM5C | P41229 | 3/20 | 0.45 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.45 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.45 |
| ▸ | KDM6B | O15054 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL27570614 | 0.96 | LMNA (0.64) | LMNAEGLN1ALKBH5SUCNR1APEX1 | |
| Succinic Acid SCHEMBL7784488 | 0.96 | LMNA (0.64) | LMNAEGLN1ALKBH5SUCNR1APEX1 | |
| Succinic Acid SCHEMBL28789402 | 0.96 | LMNA (0.64) | LMNAEGLN1ALKBH5SUCNR1APEX1 | |
| Adipic Acid SCHEMBL540745 | 0.86 | LMNA (0.73) | LMNASLC22A6OR51E2TSHRNFKB1 | |
| Glutarate SCHEMBL540985 | 0.86 | SLC22A6 (0.73) | LMNAEGLN1ALKBH5SUCNR1APEX1 | |
| Succinic Acid SCHEMBL9695227 | 0.86 | EGLN1 (0.60) | LMNAEGLN1ALKBH5SUCNR1APEX1 | |
| Succinic Acid SCHEMBL11335766 | 0.86 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1APEX1 | |
| Succinic Acid SCHEMBL27383830 | 0.86 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1APEX1 | |
| Succinic Acid SCHEMBL31266385 | 0.86 | LMNA (0.60) | LMNAEGLN1ALKBH5SUCNR1APEX1 | |
| Succinic Acid SCHEMBL9819357 | 0.85 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111793479-B | Oil-based drilling fluid and preparation method thereof | 中国海洋石油集团有限公司 | 2022-08-02 | — | — | CN | claimed |
| CN-111793479-A | Oil-based drilling fluid and preparation method thereof | 中国海洋石油集团有限公司 | 2020-10-20 | — | — | CN | claimed |
| CN-106008947-B | A kind of succinate sulfate and its synthetic method | 中国日用化学工业研究院 | 2018-06-01 | — | — | CN | claimed |
| CN-106008947-A | Succinate sulfate and synthesis method thereof | 中国日用化学工业研究院 | 2016-10-12 | — | — | CN | claimed |
| US-7485636-B2 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | PFIZER INC. (US) | 2009-02-03 | — | — | US | claimed |
| CN-118302422-A | Substituted N-cyanopyrrolidines having activity as USP30 inhibitors | 特殊治疗有限公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4157834-B1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LTD (GB) | 2024-07-03 | — | — | EP | disclosed |
| CN-114341133-B | Substituted cyanopyrrolidines having USP30 inhibitor activity | 特殊治疗有限公司 | 2024-02-27 | — | — | CN | disclosed |
| US-20230312580-A1 | 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS | MISSION THERAPEUTICS LIMITED (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | MISSION THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| CN-114507514-B | Bridging plugging agent and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | HIRANO MISATO (JP) | 2003-11-27 | — | — | US | disclosed |
| WO-2003087061-A1 | PYRAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003086390-A1 | IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| CN-1035497-A | The inhibitor of lysyloxidase | MERRELL DOW PHARMA (US) | 1989-09-13 | — | — | CN | disclosed |
| US-4512552-A | FOR FERROUS METALS, INORGANIC ACID, CARBOXY ACID, HEAVY METAL, AND A POLYMER | KATAYAMA CHEMICAL WORKS CO., LTD. (JP) | 1985-04-23 | — | — | US | disclosed |
| US-4201235-A | TOPICAL APPLICATION | Mare Corporation (US) | 1980-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219939-A1 | N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION | USP30, UQCRC1, NDUFAF1 | LMNA 2123/4885EGLN1 381/4885ALKBH5 2591/4885 |
| US-20230312580-A1 | 1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS | USP30, USP1, USP28 | LMNA 2917/4885EGLN1 250/4885ALKBH5 1488/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | LMNA 3215/4885EGLN1 1347/4885ALKBH5 4574/4885 |
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP1, USP47 | LMNA 1646/4885EGLN1 760/4885ALKBH5 2583/4885 |
| US-20030220372-A1 | Imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, PTGES | LMNA 4151/4885EGLN1 1038/4885ALKBH5 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.